•PhD in Biochemistry, Biological or chemistry sciences
•3-5 years pharmaceutical industry experience
•Experience or working in matrix across departmental lines
•Extensive knowledge chemistry of biotransformation or metabolism, and
ability to apply their experience to drug discovery, development or
post-marketing area issues.
•Strong experience applying in vitro/ex-vivo technologies and in
vitro/ex-vivo to in vivo extrapolation to investigative safety issues.
•Strong communication skills (e.g., writing, speaking)
•Strong experience in project issue resolution relevant to drug safety
and the development of novel scientific approaches for mechanistic
•PhD with specilization in Drug Metabolism
with application to drug discovery, development and registration of new
•Demonstrated networking skills with external key opinion leaders and
experts in scientific disciplines and effectively communicates findings
to internal groups.
Supports and develops others by acting as a coach or mentor, by
allocating important projects and challenging responsibilities to
others for the purpose of their development.
•Strong communication skills (e.g., writing, speaking).
•Ability to build strong communication networks, share knowledge
effectively across departments and divisions and establish cross
functional matrix groups.
•Strong leadership skills demonstrating vision and strategy
Provide deep scientific knowledge and expertise in xenobiotic
biotransformation and metabolite formation mechanisms, and to work
alongside other experts to relate these findings to the safety of
medicines in patients. To act as a key opinion leader to the wider
community of scientists across the MSD line, to PTS and the wider GSK.
• Develop the scientific strategy, along with other experts, to improve
our understanding of xenobiotic chemistry and their biotransformation
pathways (structural alerts) and how these link to biological
mechanisms of toxicity and thus provide a better association of
Molecular Initiating Events with Adverse Outcome Pathways e.g.,
xenobiotics effects on genome, proteome, metabolome, and what
predisposes certain population to adverse events.
• Collaborate with the Computational & Modelling Science group and
the rest of MSD to integrate these findings into qualitative systems
biology models and routinely discuss experiments to test hypotheses.
• Work with Insight from Data and Computational & Modelling Science
groups to use or to help create knowledge databases to develop SAR’s
using retrospective and competitor information and establish relational
rules for toxicity e.g. moiety x likely to be mutagenic (DEREK),
covalent binding to proteins leading to idiosyncratic drug reactions.
Use in silico predictions where possible.
• Advance our knowledge of the enzymes their impact on
preclinical-clinical translation (species differences) and prediction
of clinical variability in patient populations (polymorphisms, DDIs,
impact of disease).
• Evaluate/direct potential innovative drug
metabolism/biotransformation research areas and/or apply innovative
solutions to project problems, including design of bespoke studies and
application of differential development. Develop a scientific
strategy in this area with a 12 – 18 month planning horizon.
• Contextualize and extrapolate drug metabolism/biotransformation
findings and discuss data with program/project teams, internal advisory
groups as well as Senior Leaders & Regulators
• Represent GSK on external working groups to advance our understanding
of drug metabolism / biotransformation mechanisms from preclinical
findings to the clinical setting by working with industry (e.g.
cross-industry consortia, IQ, IMI,) and academia as well as regulatory
groups. Closely follow and critique primary literature to maintain
• Critique, influence and represent ‘ADME’ for PTS on a range of
topics, including drug metabolism, biotransformation mechanisms,
enzymology, modeling and, where appropriate drug transporters.
• Communicate, interact and influence others and acts as mentor, coach,
trainer and consultant in understanding biotransformation pathways.
• Publishes regularly in relevant journals and provide
authorship/review of high quality reports, publications, regulatory